Apton Biosystems has developed a high-throughput, low-cost sequencing platform that will revolutionize the availability and affordability of genetic analysis. With its innovative Cloud Sequencing™ business model, Apton will expand sequencing demand and impact by providing flexible and cost efficient access to sequencing data on demand. The platform will enable biomarker discovery, early disease detection and therapeutic monitoring by advancing the discovery and delivery of new sequencing applications
Chief Executive Officer, Ph.D.
Ellen Beasley was named Apton Biosystems’ CEO in April 2019. She has over 25 years of experience in genomics sciences, applied diagnostics, personalized medicine and research tools development. Prior to joining Apton Ellen was SVP of Product & Services R&D at Genomic Health where she focused on the application of next generation technologies, including sequencing and liquid-based biopsy, to discover and develop Genomic Health’s next generation of products to serve patients living with cancer. In 2017, Ellen was named one of the Most Influential Women in Business by San Francisco Business Times. Ellen started her career in human genomics at the Stanford Human Genome Center mapping the human genome. She then moved to Celera Genomics to work on genome sequencing and gene discovery efforts for the human genome. Ellen moved to Perlegen Sciences, serving as SVP of R&D Operations managing companion diagnostic programs and establishing a CLIA lab. Ellen then joined Life Technologies as Vice President of Biological Information Systems, leading a team to develop methods and software tools to exploit the data from next generation sequencers. Ellen has a Bachelor of Science in Biology from Trinity College (Hartford, CT) and a Ph.D. in Molecular Genetics and Cell Biology from The University of Chicago, she completed post-doctoral training at the Biozentrum of the University of Basel in Switzerland and Stanford University. She is an inventor on approximately 185 patents.